Mjp Associates Inc Bristol Myers Squibb CO Transaction History

Mjp Associates Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	BUY	$47.98 - $54.4 $177,621 - $201,388	3,702 New	3,702 $200,000
Q3 2023 Oct 10, 2023	SELL	$57.89 - $64.73 $145,188 - $162,342	-2,508 Reduced 33.47%	4,985 $289,000
Q2 2023 Jul 11, 2023	SELL	$63.71 - $70.74 $54,344 - $60,341	-853 Reduced 10.22%	7,493 $479,000
Q1 2023 Apr 17, 2023	SELL	$65.71 - $74.53 $1,642 - $1,863	-25 Reduced 0.3%	8,346 $578,000
Q4 2022 Jan 20, 2023	BUY	$68.48 - $81.09 $18,968 - $22,461	277 Added 3.42%	8,371 $0
Q3 2022 Oct 12, 2022	SELL	$0.13 - $76.84 $4 - $2,689	-35 Reduced 0.43%	8,094 $575,000
Q2 2022 Jul 11, 2022	SELL	$72.62 - $79.98 $101,159 - $111,412	-1,393 Reduced 14.63%	8,129 $626,000
Q1 2022 Apr 19, 2022	BUY	$61.48 - $73.72 $140,727 - $168,745	2,289 Added 31.65%	9,522 $696,000
Q4 2021 Jan 18, 2022	BUY	$53.63 - $62.52 $10,189 - $11,878	190 Added 2.7%	7,233 $448,000
Q3 2021 Oct 13, 2021	SELL	$59.17 - $69.31 $90,530 - $106,044	-1,530 Reduced 17.85%	7,043 $417,000
Q2 2021 Jul 14, 2021	SELL	$61.91 - $67.42 $5,757 - $6,270	-93 Reduced 1.07%	8,573 $573,000
Q1 2021 May 04, 2021	BUY	$59.34 - $66.74 $1,186 - $1,334	20 Added 0.23%	8,666 $547,000
Q4 2020 Jan 27, 2021	BUY	$57.74 - $65.43 $499,220 - $565,707	8,646 New	8,646 $536,000

2,425

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Mjp Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Mjp Associates Inc with notifications on news.